Holmusk is building the largest suite of real-world evidence solutions, starting with neuropsychiatry. We are on a mission to reinvent neuropsychiatry and transform lives through real-world data, AI-powered analytics, and custom services.
It is time to rethink how we approach neuropsychiatry. Neuropsychiatry encompasses many mental, emotional, and social factors that contribute to overall well-being, and has profound impacts on individuals, healthcare systems, and economies.
Over 970 million people worldwide suffer from mental illness and substance use disorders, contributing to over US $1 trillion in economic burden each year, but unique barriers have hindered progress for too long.
Unique barriers in neuropsychiatry
The reliance on subjective assessments, a lack of standardized terminology and insufficient biomarkers or lab tests, limits data collection and makes accurate measurement for neuropsychiatry problematic.
Heterogeneous genetic, biological, and environmental risk factors create major challenges for both research and therapeutic innovation.
Real-world evidence (RWE) is based on analyzing real-world data (RWD), including information on health status, process, outcomes, and care delivery, as they occur in everyday settings.
Today, the bulk of clinical evidence is based on stringent randomized controlled trials and observational studies, which only include a small minority (<2%) of patients who ultimately are treated.
Evidence to accelerate progress
Support new therapies for neuropsychiatry entering the market and end the 20 years of therapeutic stagnation.
Leverage RWE to guide care for different patient cohorts and optimize treatment options for the future of personalized care.
